Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort study.

Bui, Ai-Tram N; Bougrine, Amina; Buchbinder, Elizabeth I; Giobbie-Hurder, Anita; LeBoeuf, Nicole R

Bui, Ai-Tram N; Bougrine, Amina; Buchbinder, Elizabeth I; Giobbie-Hurder, Anita; LeBoeuf, Nicole R.

Afiliação

Bui AN; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Bougrine A; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Buchbinder EI; Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
Giobbie-Hurder A; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
LeBoeuf NR; Harvard Medical School, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts. Electronic address: nle

J Am Acad Dermatol ; 87(2): 403-406, 2022 08.

Article em En | MEDLINE | ID: mdl-34252467

Assuntos

Inibidores de Checkpoint Imunológico; Melanoma; Feminino; Humanos; Inibidores de Checkpoint Imunológico/efeitos adversos; Ipilimumab/efeitos adversos; Estudos Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Melanoma Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google